These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34166315)

  • 21. The epidemiology of HIV population viral load in twelve sub-Saharan African countries.
    Hladik W; Stupp P; McCracken SD; Justman J; Ndongmo C; Shang J; Dokubo EK; Gummerson E; Koui I; Bodika S; Lobognon R; Brou H; Ryan C; Brown K; Nuwagaba-Biribonwoha H; Kingwara L; Young P; Bronson M; Chege D; Malewo O; Mengistu Y; Koen F; Jahn A; Auld A; Jonnalagadda S; Radin E; Hamunime N; Williams DB; Kayirangwa E; Mugisha V; Mdodo R; Delgado S; Kirungi W; Nelson L; West C; Biraro S; Dzekedzeke K; Barradas D; Mugurungi O; Balachandra S; Kilmarx PH; Musuka G; Patel H; Parekh B; Sleeman K; Domaoal RA; Rutherford G; Motsoane T; Bissek AZ; Farahani M; Voetsch AC
    PLoS One; 2023; 18(6):e0275560. PubMed ID: 37363921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.
    Gottlieb GS; Badiane NM; Hawes SE; Fortes L; Toure M; Ndour CT; Starling AK; Traore F; Sall F; Wong KG; Cherne SL; Anderson DJ; Dye SA; Smith RA; Mullins JI; Kiviat NB; Sow PS;
    Clin Infect Dis; 2009 Feb; 48(4):476-83. PubMed ID: 19143530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV care coverage among HIV-positive adolescent girls and young women in South Africa: Results from the HERStory Study.
    Mathews C; Cheyip M; Beauclair R; Puren A; Lombard C; Jonas K; Ayalew KA; Govindasamy D; Kuo C; Dietrich J; Abdullah F; Gray G
    S Afr Med J; 2021 Apr; 111(5):460-468. PubMed ID: 34852889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061.
    Chen I; Connor MB; Clarke W; Marzinke MA; Cummings V; Breaud A; Fogel JM; Laeyendecker O; Fields SD; Donnell D; Griffith S; Scott HM; Shoptaw S; del Rio C; Magnus M; Mannheimer S; Wheeler DP; Mayer KH; Koblin BA; Eshleman SH
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):446-52. PubMed ID: 25861015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of taking or not taking ARVs on HIV stigma as reported by persons living with HIV infection in five African countries.
    Makoae LN; Portillo CJ; Uys LR; Dlamini PS; Greeff M; Chirwa M; Kohi TW; Naidoo J; Mullan J; Wantland D; Durrheim K; Holzemer WL
    AIDS Care; 2009 Nov; 21(11):1357-62. PubMed ID: 20024711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
    Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
    J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Early Antiretroviral Treatment Initiation on Performance of Cross-Sectional Incidence Assays.
    Klock E; Mwinnya G; Eller LA; Fernandez RE; Kibuuka H; Nitayaphan S; Kosgei J; Moore RD; Robb M; Eshleman SH; Laeyendecker O
    AIDS Res Hum Retroviruses; 2020 Jul; 36(7):583-589. PubMed ID: 32295382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort.
    Hauser A; Santos-Hoevener C; Meixenberger K; Zimmermann R; Somogyi S; Fiedler S; Hofmann A; Bartmeyer B; Jansen K; Hamouda O; Bannert N; Kuecherer C
    PLoS One; 2014; 9(6):e98038. PubMed ID: 24892795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of rilpivirine in HIV-1-infected individuals in routine clinical practice from 2012 to 2017 in France.
    Potard V; Gallien S; Canestri A; Costagliola D;
    J Antimicrob Chemother; 2021 Jan; 76(2):467-476. PubMed ID: 33257955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.
    Wendel SK; Mullis CE; Eshleman SH; Blankson JN; Moore RD; Keruly JC; Brookmeyer R; Quinn TC; Laeyendecker O
    PLoS One; 2013; 8(2):e55525. PubMed ID: 23437058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance.
    Sempa JB; Welte A; Busch MP; Hall J; Hampton D; Facente SN; Keating SM; Marson K; Parkin N; Pilcher CD; Murphy G; Grebe E;
    PLoS One; 2019; 14(7):e0220345. PubMed ID: 31348809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detectable Viral Load in Late Pregnancy among Women in the Rwanda Option B+ PMTCT Program: Enrollment Results from the Kabeho Study.
    Gill MM; Hoffman HJ; Bobrow EA; Mugwaneza P; Ndatimana D; Ndayisaba GF; Baribwira C; Guay L; Asiimwe A
    PLoS One; 2016; 11(12):e0168671. PubMed ID: 28006001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies.
    Duong YT; Qiu M; De AK; Jackson K; Dobbs T; Kim AA; Nkengasong JN; Parekh BS
    PLoS One; 2012; 7(3):e33328. PubMed ID: 22479384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France.
    Potard V; Canestri A; Gallien S; Costagliola D;
    J Antimicrob Chemother; 2019 Nov; 74(11):3305-3314. PubMed ID: 31384941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda.
    Longosz AF; Serwadda D; Nalugoda F; Kigozi G; Franco V; Gray RH; Quinn TC; Eshleman SH; Laeyendecker O
    AIDS Res Hum Retroviruses; 2014 Apr; 30(4):339-44. PubMed ID: 24083837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection.
    Novitsky V; Wang R; Kebaabetswe L; Greenwald J; Rossenkhan R; Moyo S; Musonda R; Woldegabriel E; Lagakos S; Essex M
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):265-72. PubMed ID: 19525854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experiences and lessons learned from the real-world implementation of an HIV recent infection testing algorithm in three routine service-delivery settings in Kenya and Zimbabwe.
    de Wit MM; Rice B; Risher K; Welty S; Waruiru W; Magutshwa S; Motoku J; Kwaro D; Ochieng B; Reniers G; Cowan F; Rutherford G; Hargreaves JR; Murphy G
    BMC Health Serv Res; 2021 Jun; 21(1):596. PubMed ID: 34158047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV drug resistance in a community-randomized trial of universal testing and treatment: HPTN 071 (PopART).
    Fogel JM; Wilson EA; Piwowar-Manning E; Breaud A; Clarke W; Petropoulos C; Moore A; Fraser C; Kosloff B; Shanaube K; van Zyl G; Scheepers M; Floyd S; Bock P; Ayles H; Fidler S; Hayes R; Donnell D; Eshleman SH;
    J Int AIDS Soc; 2022 Jul; 25(7):e25941. PubMed ID: 35775502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.
    Gupta A; Saple DG; Nadkarni G; Shah B; Vaidya S; Hingankar N; Chaturbhuj D; Deshmukh P; Walshe L; Hudelson SE; James M; Paranjape RS; Eshleman SH; Tripathy S
    AIDS Res Hum Retroviruses; 2010 Jan; 26(1):25-31. PubMed ID: 20063995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.